Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $1,257,657.38 in Stock

Key Points

• Insider selling: Johannes Kastelein sold 50,246 NewAmsterdam Pharma shares for approximately $1.26 million, reducing his direct stake by 42.03% to 69,302 shares. He also sold 125,000 shares in August for $3.36 million.
• Recent performance: NAMS traded at $23.20, near its 52-week low of $21.02 and well below its 52-week high of $42.21. The company reported a quarterly loss of $0.52 per share, missing estimates, despite revenue exceeding expectations.
• Analyst outlook remains positive: Analysts have a consensus “Moderate Buy” rating and an average price target of $49.73, while institutional investors own 89.89% of the company.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Kastelein sold 50,246 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total transaction of $1,257,657.38. Following the sale, the insider directly owned 69,302 shares in the company, valued at approximately $1,734,629.06. This represents a 42.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, August 24th, Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock traded down $0.96 during trading hours on Friday, reaching $23.20. 1,547,726 shares of the company were exchanged, compared to its average volume of 1,137,666. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $21.02 and a fifty-two week high of $42.21. The stock's fifty day moving average is $25.69 and its two-hundred day moving average is $30.28. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -10.74 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. On average, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. boosted its position in shares of NewAmsterdam Pharma by 6.8% during the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock worth $613,033,000 after purchasing an additional 1,145,128 shares in the last quarter. Capital World Investors raised its stake in NewAmsterdam Pharma by 1.6% during the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company's stock worth $350,239,000 after buying an additional 161,289 shares during the period. Maverick Capital Ltd. lifted its holdings in NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company's stock worth $69,987,000 after acquiring an additional 292,176 shares in the last quarter. Castle Hook Partners LP bought a new position in NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Finally, First Turn Management LLC grew its stake in NewAmsterdam Pharma by 24.6% in the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company's stock valued at $31,343,000 after acquiring an additional 176,502 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NAMS has been the topic of several recent research reports. Royal Bank Of Canada decreased their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Jefferies Financial Group reiterated a "buy" rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an "outperform" rating and a $58.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $52.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $49.73.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company's lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.